Table 2.
Population median parameter estimates for the combination therapy mathematical model.
| Parameter | Symbol (unit) | Population median estimates | |
|---|---|---|---|
| Median | 95% C.I.a | ||
| Maximal amount of replicon levels | POPMAX (Log10 RLU) | 21.446 | |
| First-order replicon turnover rate for susceptible replicon population | Kturn-s (day−1) | 0.650 | |
| First-order rate of loss of replicon from cells for susceptible replicon population | Kloss-s (day−1) | 0.670 | |
| Effective concentration 50 value of LDV for susceptible replicon population | EC50-D1s (pg/ml) | 4.147 | |
| Effective concentration 50 value of SOF for susceptible replicon population | EC50-D2s (pg/ml) | 57,356 | |
| Drug interaction term for effect for susceptible replicon population | αs | 0.315 | −0.15–2.4 |
| First-order replicon turnover rate for replicons resistant to LDVb | Kturn-R1 (day−1) | 0.815 | |
| First-order rate of loss of replicon from cells for LDV-resistant replicons | Kloss-R1 (day−1) | 0.793 | |
| Effective concentration 50 value of LDV for replicons resistant to LDV | EC50-D1R (pg/ml) | 18.625 | |
| Drug interaction term for effect for LDV-resistant replicons | αD1r | 0.334 | −2.6–0.63 |
| Hill constant for susceptible replicon population to LDV | HD1-s | 0.997 | |
| Hill constant for suscpetible replicon population to SOF | HD2-s | 2.985 | |
| Hill constant for replicons resistant to LDV | HD1-R | 3.253 | |
a95% confidence Interval (C.I.) was determined by bootstrap analysis. bReplicons harboring RAVs to SOF were not detected in this study.